Completed a convertible note financing of our client Breonics by Fischli Venture Partners. Breonics has developed a new and innovative technology called Exsanguinous Metabolic Support (EMS), which enables the continued function of organs and tissues outside the human body from within minutes of death to a window of several hours postmortem. EMS radically broadens the criteria for kidney donors to include the huge cohort of patients that die every year and were previously not considered for donation.